{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-005455","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.002677+00:00","generated_at":"2026-05-27T13:18:56.511881+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Traws Pharma completes Phase 1 studies for single-dose bird flu drug tivoxavir marboxil","bullets":["Phase 1 trial showed safety, tolerability, and PK supporting dosing for H5N1 treatment and prevention.","No significant treatment-related adverse events reported across four dose levels in healthy volunteers.","Preclinical data showed potent inhibition of drug-resistant and highly pathogenic bird flu viruses.","Company plans to use data to guide upcoming regulatory meetings for accelerated development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-005455","json":"https://secwatch.observer/filing/0001104659-25-005455.json","markdown":"https://secwatch.observer/filing/0001104659-25-005455.md","text":"https://secwatch.observer/filing/0001104659-25-005455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/0001104659-25-005455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/tm253126d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T13:18:56.511881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}